What Is Multiple Sclerosis?

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (brain, spinal cord, and optic nerves) in which the immune system attacks myelin — the protective layer that surrounds nerve fibers. This demyelination causes disturbances in nerve impulse conduction, resulting in a wide variety of neurological symptoms.

The name "multiple sclerosis" describes the multiple áreas of scarring (sclerosis) that form in the brain and spinal cord after episodes of inflammation and demyelination. These lesions, called plaques, can be visualized by magnetic resonance imaging and are the hallmark of the disease.

MS predominantly affects young adults between 20 and 40 years old, with female predominance (2-3:1). It is the most common cause of nontraumatic neurological disability in young adults. Prevalence varies significantly by geographic region and is higher in latitudes far from the equator.

1

Autoimmune Disease

The immune system mistakenly attacks central nervous system myelin, causing inflammation, demyelination, and progressive axonal damage.

2

Disseminated Lesions

Demyelination plaques scattered throughout the brain and spinal cord cause diverse and unpredictable neurological symptoms.

3

Variable Course

MS can follow different patterns — relapses and remissions, gradual progression, or combined forms. Early treatment significantly alters the disease course.

Pathophysiology

MS is an immune-mediated disease in which autoreactive T and B lymphocytes cross the blood-brain barrier and trigger an inflammatory cascade against myelin components. The exact trigger of this autoimmunity remains unknown but involves an interaction between genetic predisposition and environmental factors.

Pathophysiology of multiple sclerosis: T and B lymphocytes crossing the blood-brain barrier, attack on the myelin sheath, demyelination, axonal damage, and formation of sclerotic plaques with partial remyelination
Pathophysiology of multiple sclerosis: T and B lymphocytes crossing the blood-brain barrier, attack on the myelin sheath, demyelination, axonal damage, and formation of sclerotic plaques with partial remyelination

Demyelination and Axonal Damage

In the acute inflammatory phase (relapse), CD4+ and CD8+ T lymphocytes infiltrate the brain parenchyma and release pro-inflammatory cytokines, activating macrophages and microglia that phagocytize myelin. Antibodies produced by B cells also contribute to damage. The resulting demyelination blocks or slows nerve impulse conduction.

In addition to demyelination, progressive axonal damage occurs from the early phases of the disease. The loss of myelin exposes axons to metabolic stress (inability to maintain ionic gradients efficiently), leading to axonal degeneration. It is this axonal damage, not demyelination itself, that is the main determinant of irreversible disability.

Risk Factors

Identified risk factors include: vitamin D deficiency (strong association with latitude and sun exposure), prior infection with Epstein-Barr virus (about 32-fold higher risk in individuals who seroconverted to EBV during follow-up), smoking (increases risk and accelerates progression), obesity in adolescence, and genetics (HLA-DRB1*15:01 and other polymorphisms).

Symptoms

MS symptoms are extremely variable and depend on lesion location in the central nervous system. This unpredictability is one of the most challenging features of the disease for patients and physicians.

Clinical forms of multiple sclerosis: relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS), with typical disability evolution over time
Clinical forms of multiple sclerosis: relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS), with typical disability evolution over time

Common Symptoms of Multiple Sclerosis

  • Optic neuritis

    Optic nerve inflammation causing pain on eye movement and vision loss. Often the first symptom of MS, especially in young people.

  • Fatigue

    Tiredness disproportionate to effort, present in up to 80% of patients. It is the most common symptom and one of the most disabling.

  • Paresthesias and numbness

    Tingling, numbness, or abnormal sensations in limbs or trunk. They can affect extensive áreas or follow a "band" pattern on the trunk.

  • Muscle weakness

    Can affect one or more limbs. Leg weakness is more common and affects gait.

  • Spasticity

    Increased muscle tone, especially in the legs. Causes stiffness, painful spasms, and gait difficulty.

  • Ataxia and incoordination

    Difficulty coordinating movement and balance, caused by cerebellar lesions or proprioceptive pathway involvement.

  • Urinary disturbances

    Urinary urgency, frequency, and incontinence in up to 80% of patients over the course of the disease.

  • Neuropathic pain

    Burning, stabbing, or shock-like pain (including trigeminal neuralgia) present in 50-70% of patients.

  • Cognitive dysfunction

    Difficulty with concentration, information processing, and memory in 40-65% of patients. Often underestimated.

  • Lhermitte's sign

    Sensation of an electric shock running down the spine when flexing the neck — indicates a cervical cord lesion. Relatively specific to MS.

Clinical Forms of Multiple Sclerosis

FormFeaturesFrequency
Relapsing-remitting (RRMS)Relapses (episodes of new symptoms or worsening) followed by partial or complete remission85% at diagnosis
Secondary progressive (SPMS)Gradual progression of disability, with or without superimposed relapsesEvolves from RRMS in 50% after 15-20 years
Primary progressive (PPMS)Gradual progression from onset, without defined relapses10-15% of cases
Progressive-relapsingProgression from the beginning with superimposed relapsesRare (5%)
2.8 million
people affected worldwide
20-40 years
typical age of onset
2-3:1
female predominance
85%
start as the relapsing-remitting form

Diagnosis

Diagnosis of MS is based on the McDonald criteria (revised in 2017), which require demonstration of dissemination in space (lesions in multiple CNS locations) and dissemination in time (lesions at different moments). MRI is the most important test for diagnosis.

MRI in multiple sclerosis: periventricular, juxtacortical, infratentorial, and spinal cord demyelinating lesions (McDonald criteria)
MRI in multiple sclerosis: periventricular, juxtacortical, infratentorial, and spinal cord demyelinating lesions (McDonald criteria)

MS Diagnostic Pillars (McDonald Criteria 2017)

  1. Dissemination in space: lesions in at least 2 of 4 typical áreas (periventricular, cortical/juxtacortical, infratentorial, spinal cord)
  2. Dissemination in time: lesions with and without gadolinium enhancement simultaneously, OR new T2/enhancing lesion on subsequent MRI
  3. MRI: multiple lesions on T2/FLAIR in typical locations. Gold standard for demonstrating dissemination
  4. Cerebrospinal fluid: oligoclonal bands present in 95% of MS patients (support diagnosis, especially in progressive forms)
  5. Evoked potentials: can demonstrate subclinical demyelination in visual, somatosensory, or auditory pathways
  6. Exclusion of mimickers: neuromyelitis optica, lupus, sarcoidosis, vasculitis, vitamin B12 deficiency

Differential Diagnosis

Multiple sclerosis is one of the neurological diseases with the most clinical mimickers. Rigorous differential diagnosis is essential because disease-modifying therapies are specific to MS and should not be used in other conditions.

Differential Diagnosis

Neuromyelitis Optica (NMOSD)

  • Severe bilateral optic neuritis
  • Extensive transverse myelitis
  • Anti-AQP4 positive
Warning signs
  • NMOSD has worse prognosis — differential diagnosis crucial
Diagnostic testsAnti-AQP4Anti-MOGSpinal MRI

Systemic Lupus Erythematosus

  • Systemic symptoms
  • ANA positive
  • Can cause brain lesions
Diagnostic testsANAAnti-double-stranded DNAComplement

CNS Sarcoidosis

  • CNS lesions with systemic sarcoidosis
  • Elevated ACE
  • Hilar adenopathy
Diagnostic testsSerum ACEPET-CTBiopsy

Progressive Multifocal Leukoencephalopathy

  • Immunosuppressed (HIV, biologics use)
  • JC virus positive
  • Progressive without remission
Diagnostic testsJC PCR in CSFMRI

Migraine with Aura

Read more
  • Recurrent episodes with aura
  • No progressive déficit
  • Associated headache
Diagnostic testsICHD-3 criteriaMRI without T2 lesions

MS vs Neuromyelitis Optica: Critical Distinction

Neuromyelitis optica (NMOSD) is the most important differential diagnosis for MS, especially because its treatment differs and inadvertent use of certain MS immunomodulators (such as natalizumab, fingolimod) can worsen NMOSD. NMOSD is characterized by severe optic neuritis with severe vision loss (often bilateral), extensive transverse myelitis (lesions covering 3 or more segments on spinal MRI), and positive anti-AQP4 (aquaporin-4) antibody in 70-80% of cases. Anti-MOG is positive in a more benign form (MOGAD). Negativity of both antibodies plus a typical MS MRI points toward an MS diagnosis.

Systemic lupus erythematosus can cause neurological manifestations identical to MS, including white-matter brain lesions, episodes of focal neurological deficits, and CSF alterations. The distinction rests on systemic manifestations (arthritis, malar rash, serositis, nephritis), high-titer ANA positivity, anti-double-stranded DNA, and reduced complement. In young women with suspected MS, lupus workup should be systematic.

Progressive Multifocal Leukoencephalopathy: Alert in the Immunosuppressed

Progressive multifocal leukoencephalopathy (PML), caused by the JC virus, is a serious complication of immunosuppressed states — including MS patients on natalizumab or other biologics. It can be mistaken for an MS relapse or disease progression. Characteristically, PML is progressive without remission, can affect the cerebellum and brainstem asymmetrically, and MRI shows lesions without contrast enhancement (unlike active MS relapses) with specific patterns. JC virus PCR in CSF is confirmatory. In MS patients on high-efficacy therapies, any new progression should raise suspicion of PML.

CNS sarcoidosis is a rare but important mimicker, especially when periventricular MRI lesions resemble MS plaques. Systemic manifestations (bilateral hilar adenopathy, uveitis, skin lesions), elevated angiotensin-converting enzyme, and the MRI lesion pattern (tendency to affect meninges, cranial nerves, and hypothalamus) help with diagnosis. Biopsy of an accessible lesion (salivary gland, lymph node) often confirms sarcoidosis without the need for brain biopsy.

Migraine with Aura: The Most Frequent Mimicker

Migraine with aura is probably the diagnosis most often confused with MS, especially in young women. Migraine aura can include visual (scintillating scotoma), sensory (unilateral paresthesias), and speech symptoms that set in slowly and progressively (characteristically over 5-20 minutes) and resolve spontaneously in less than 60 minutes. The white-matter lesions seen on migraineurs' MRIs (called UBOs — unidentified bright objects) can mimic MS plaques but are generally smaller, lack typical MS location features, and do not increase over time.

Rigorous application of the McDonald 2017 criteria — dissemination in space (lesions in at least 2 of the 4 typical regions) and time — and the use of CSF oligoclonal bands are the elements that distinguish MS from migraine with nonspecific lesions. Detailed clinical history, including previous episodes of neurological déficit, symptom pattern, and migraine diagnostic criteria (ICHD-3), is essential for differential diagnosis.

Multiple sclerosis

  • The McDonald 2017 criteria require dissemination in space and time.
  • Lesions follow the typical MS distribution.
  • CSF oligoclonal bands help distinguish it from migraine with nonspecific lesions.

Migraine with aura

  • The aura sets in slowly and progressively, characteristically over 5-20 minutes.
  • The aura resolves spontaneously in less than 60 minutes.
  • White-matter lesions (UBOs) are generally smaller, lack typical MS location features, and do not increase over time.

Treatment

MS treatment comprises three components: relapse treatment, disease-modifying therapies (DMTs) to prevent relapses and progression, and symptomatic treatment for management of specific symptoms such as pain, spasticity, and fatigue.

Relapse Treatment

High-dose corticosteroids (methylprednisolone 1 g IV for 3-5 days) are the standard treatment for acute relapses. They speed recovery from the relapse through anti-inflammatory effect and restoration of the blood-brain barrier, but do not alter the final degree of recovery. For relapses refractory to corticosteroids, plasmapheresis may be indicated.

Disease-Modifying Therapies

DMTs revolutionized MS treatment, reducing relapses, new lesions, and disability progression. More than 20 DMTs are available, varying in efficacy and safety profile. The current trend is to start with high-efficacy therapies early.

Options include injectable therapies (interferons, glatiramer acetate), oral (fingolimod, dimethyl fumarate, teriflunomide, cladribine, siponimod), infusions (natalizumab, ocrelizumab, alemtuzumab), and subcutaneous antibody injection (ofatumumab). The choice depends on disease activity, risk profile, patient preference, and accessibility.

Therapeutic Approaches in MS

CategoryExamplesIndication
Moderate efficacyInterferons, glatiramer acetate, teriflunomide, dimethyl fumarateMild to moderate forms, patients with low disease activity
High efficacyNatalizumab, fingolimod, ocrelizumab, cladribineActive disease, patients with frequent relapses or active lesions on MRI
InductionAlemtuzumab, bone marrow transplantVery active disease, refractory to high-efficacy therapies
ProgressiveOcrelizumab (PPMS), siponimod (SPMS)Progressive forms — limited but growing options

Symptomatic Treatment

Symptom management is fundamental for quality of life. Spasticity: baclofen, tizanidine, botulinum toxin. Neuropathic pain: pregabalin, gabapentin, amitriptyline. Fatigue: regular physical exercise (best evidence), amantadine, modafinil. Bladder dysfunction: anticholinergics, intravesical botulinum toxin. Physical therapy and rehabilitation are essential components of overall treatment.

Do

  • Do regular physical exercise, which has the best evidence for fatigue
  • Keep the disease-modifying therapies prescribed by the neurologist, even when using complementary therapies
  • Treat specific symptoms such as pain, spasticity, and fatigue, because symptom management is fundamental for quality of life

Avoid

  • Use acupuncture as a substitute for conventional treatment
  • Discontinue the disease-modifying therapy without medical guidance
  • Replace disease-modifying therapies with highly restrictive diets or unproven supplements
The essentials so far
  1. MS treatment comprises three components: relapse treatment, disease-modifying therapies, and symptomatic treatment.
  2. High-dose corticosteroids are the standard treatment for acute relapses.
  3. Disease-modifying therapies reduce relapses, new lesions, and disability progression.
Continue: Acupuncture as treatment

Acupuncture as Treatment

Acupuncture is not a treatment for the disease itself — disease-modifying therapies are irreplaceable for controlling MS inflammatory activity. However, acupuncture has been investigated as a complementary therapy for symptom management such as pain, spasticity, fatigue, and bladder dysfunction.

Observational studies and small clinical trials suggest potential benefit for neuropathic pain, spasticity, and fatigue in MS patients. Proposed mechanisms include immune response modulation (immunomodulatory effect), endorphin release for pain relief, muscle tone regulation via modulation of spinal reflexes, and improved sleep quality.

Acupuncture must be used as a complement to conventional treatment, never as a substitute. MS patients using complementary therapies should always maintain the disease-modifying therapies prescribed by their neurologist.

Prognosis

MS prognosis is highly variable. Favorable prognostic factors include female sex, onset with optic neuritis or sensory symptoms, complete recovery from the first relapses, low MRI lesion burden, and early initiation of high-efficacy therapy.

Disease-modifying therapies have dramatically changed MS prognosis. Patients diagnosed and treated today have significantly better prospects than those of two decades ago. Life expectancy, though slightly reduced (5-10 years), is approaching that of the general population with modern treatment.

Most patients with RRMS maintain walking ability for 20-25 years after diagnosis. The concept of "benign MS" (minimal disability after 15 years) applies to 10-20% of patients, though this group can eventually progress. Regular physical activity, non-smoking, and maintenance of adequate vitamin D levels are important modifiable factors.

50%
of RRMS patients evolve to SPMS in 15-20 years
10-20%
present a benign course after 15 years
Substantial
reduction in relapse rate with high-efficacy DMTs, depending on the drug and comparator
20-25 years
mean time until need for walking aid (untreated)

Myths and Facts

Myth vs. Fact

Myth

Multiple sclerosis is a wheelchair sentence

Fact

With modern treatments, most patients maintain functional independence for decades. Disease-modifying therapies have dramatically changed the prognosis.

Myth

MS patients should not exercise

Fact

Regular physical exercise is strongly recommended and has proven benefits on fatigue, mood, muscle strength, and quality of life. Excessive heat should be avoided.

Myth

MS and amyotrophic lateral sclerosis (ALS) are the same thing

Fact

They are completely different diseases. MS is autoimmune and affects myelin. ALS is neurodegenerative and affects motor neurons. MS has many treatment options; ALS, unfortunately, still has very few.

Myth

MS prevents pregnancy

Fact

Women with MS can have healthy pregnancies. Relapse rates typically decrease during pregnancy (especially in the third trimester). Preconception planning with the neurologist is essential for medication adjustment.

Myth

Special diets cure MS

Fact

No diet has been shown to cure or significantly alter the course of MS. A balanced, healthy diet is recommended but does not replace disease-modifying therapies.

When to Seek Help

Frequently Asked Questions

Frequently Asked Questions